دورية أكاديمية
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
| العنوان: | Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. |
|---|---|
| المؤلفون: | Ribera, Jordi, Granada, Isabel, Morgades, Mireia, González, Teresa, Ciudad, Juana, Such, Esperanza, Calasanz, María-José, Mercadal, Santiago, Coll, Rosa, González-Campos, José, Tormo, Mar, García-Cadenas, Irene, Gil, Cristina, Cervera, Marta, Barba, Pere, Costa, Dolors, Ayala, Rosa, Bermúdez, Arancha, Orfao, Alberto, Ribera, Josep-Maria, Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH) |
| سنة النشر: | 2021 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | acute lymphoblastic leukaemia, adults, cytogenetic alterations, prognosis, t(1, 19)(q23, p13)/TCF3-PBX1, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Chromosome Banding, Chromosomes, Human, Pair 1, Pair 19, Disease Management, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasm, Residual, Oncogene Proteins, Fusion, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Remission Induction, Translocation, Genetic |
| الوصف: | The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1365-2141 |
| العلاقة: | http://hdl.handle.net/10668/18532Test |
| DOI: | 10.1111/bjh.17844 |
| الإتاحة: | https://doi.org/10.1111/bjh.17844Test http://hdl.handle.net/10668/18532Test |
| حقوق: | Attribution-NonCommercial-NoDerivatives 4.0 International ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.CA3306D9 |
| قاعدة البيانات: | BASE |
| تدمد: | 13652141 |
|---|---|
| DOI: | 10.1111/bjh.17844 |